Vascular effects of ranolazine in rat aorta are hypothesis-generating; clinical translation remains unproven.
Ranolazine, a piperazine derivative, is used as an anti- anginal drug to treat patients with chronic angina in clinical practice [ 1 ] and may improve coronary blood flow by reducing compression effects of ischemic contracture, and by improving endothelial function [ 2 ],[ 3 ]. In the present study we investigate the vascular effects of ranolazine on the endothelium, adrenergic system and Ca 2 + in isolated rat aorta.
No takes yet. Share an insight, caveat, or question.
Marchio et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: